| Similar Articles |
|---|
 |
The Motley Fool
June 16, 2005
Stephen D. Simpson |
Farewell, Sweet Vicuron Pfizer purchased promising biotech Vicuron Pharmaceuticals for $29.10 as share in cash. Vicuron shareholders get a nice payday -- nearly 84% premium to its close and a 21% premium to its all-time high. The deal makes sense for Pfizer despite the high sticker price.   |
The Motley Fool
May 12, 2004
Charly Travers |
Cubist Addresses a Niche Market This small firm is developing antibiotics to meet a medical need. |
The Motley Fool
June 28, 2005
Charly Travers |
Growth Around the Corner? Despite a thin pipeline, small biotech Cubist Pharmaceuticals is hoping to ride the wave of prosperity. Investors, take note. |
The Motley Fool
January 20, 2004
David Nierengarten |
Adolor's Knocked-Out Drug The biotech's stock is pummeled after mixed-up trial results. |
Chemistry World
August 11, 2014
Phillip Broadwith |
Single shot antibiotic approved for skin infections Intravenous antibiotic Orbactiv oritavancin, from US firm The Medicines Company, has been approved by the US Food and Drug Administration. |
The Motley Fool
April 8, 2005
Brian Gorman |
Cubist in Neutral Cubist Pharmaceuticals' pipeline may be why investors are unimpressed. |
Chemistry World
December 11, 2014 |
Merck to buy antibiotics specialist Cubist Hours after the deal was announced, a US District Court invalidated several key patents for Cubist's top seller, Cubicin (daptomycin). |
Chemistry World
May 6, 2014
Andy Extance |
WHO raises alarm on deadly bacteria The World Health Organization has warned antibiotic resistant bacteria could bring a nightmarish future, where seemingly trivial scrapes turn lethal, and currently routine operations become too risky to contemplate. |
BusinessWeek
October 29, 2007
Catherine Arnst |
Superbugs: Where Are the Wonder Drugs? Antibiotics are losing the battle against superbugs, and drugmakers are slow to replenish the arsenal. |
Pharmaceutical Executive
October 1, 2008
Michael Bonney |
Specialty Sales Gets No Resistance The author, a Cubist Pharmaceuticals CEO. has given his company a successful start and is now predicting the future of drug resistance. |
The Motley Fool
July 20, 2006
Brian Lawler |
Cubist's Square Results The pharmaceutical company has a promising new drug, but little else in the pipeline. Investors, take note. |
The Motley Fool
October 20, 2006
Brian Lawler |
Cubist Paints a Greener Picture The pharmaceutical company is flush with cash and finally profitable. However, it might just be easier for Cubist to sell itself to a more substantial pharmaceutical company. Investors, take note. |
The Motley Fool
September 30, 2011
Brian Orelli |
Pfizer's Fungus Failure A combination treatment doesn't work. |
The Motley Fool
October 27, 2004
Charly Travers |
Cubist's Growing Pains The pharmaceutical is going to have to work through some growing pains and make strides toward profitability before the performance of the stock will match the performance of its drug. |
The Motley Fool
January 26, 2005
Charly Travers |
Call Cubist in the Morning Strong drug sales provide a dose of good medicine for this pharmaceutical. |
The Motley Fool
July 3, 2008
Brian Lawler |
A Cubist Masterstroke Cubist Pharmaceuticals, until now a one-drug wonder, becomes a marketer of two compounds. |
Nutrition Action Healthletter
November 1999
Michael F. Jacobson |
Fighting Superbugs For more than 30 years, doctors have used the antibiotic vancomycin when all others have failed. Now vancomycin itself is starting to fail, and its successor, synercid, is already encountering resistant germs. A change in U.S. agricultural policy may be able to stem that process... |
Chemistry World
February 11, 2011
Leanne Marle |
Fighting back against antibiotic resistant bacteria Scientists in Japan have revealed how vancomycin dimers are effective against vancomycin-resistant bacteria. |
AskMen.com
Harold Russell |
The Lowdown On Superbugs The overuse and misuse of antibiotics has led to the development of resistant strains of bacteria, commonly referred to as superbugs. |
The Motley Fool
December 5, 2006
Brian Lawler |
Cubist Finds an Asian Partner The smaller drug developer teams up with AstraZeneca to bring its antibiotic to worldwide markets. The best part of the deal is that Cubist retains the rights to Cubicin in Japan, which is by far the biggest market in all of Asia. Investors, take note. |
The Motley Fool
October 20, 2011
Travis Hoium |
Cubist Pharmaceuticals Shares Popped: What You Need to Know Shares of Cubist Pharmaceuticals jumped 10% today after the company released earnings. |
American Family Physician
December 15, 2000 |
Antibiotics: When They Can and Can't Help Antibiotics are strong medicines that can stop some infections and save lives. When they aren't used the right way, antibiotics can cause more harm than good. You can protect yourself and your family by knowing when you should use antibiotics and when you should avoid them... |
American Family Physician
March 15, 2001 |
Avoiding Resistance to Antibiotics-- When Do I Need an Antibiotic? When bacteria are exposed to the same antibiotics, after a while the antibiotic can't fight the germs anymore... |
American Family Physician
February 15, 2002
Paul W. Ament |
Linezolid Its role in the treatment of gram-positive, drug-resistant bacterial infections... |
American Family Physician
July 15, 2003
Adrienne J. Headley |
Necrotizing Soft Tissue Infections: A Primary Care Review Patients with necrotizing soft tissue infections often present initially to family physicians. These infections must be detected and treated rapidly to prevent loss of limb or a fatal outcome. Unfortunately, necrotizing soft tissue infections have no pathognomonic signs. |
Nutrition Action Healthletter
May 2000 |
Magic Bullets Under Siege ...Antibiotics---drugs that kill bacteria---account for much of our success in the war against infectious illness. But the miracle drugs of medicine are in danger... |
Chemistry World
February 6, 2013
Harriet Brewerton |
Diagnosing bacterial growth Antibiotics are used regularly for treating bacterial infections, but there is currently no quick and simple test to determine the most effective type or dose of antibiotic for a specific patient infection. |
The Motley Fool
January 29, 2007
Brian Lawler |
No Dicey Results for Cubist The stock price may be down, but Cubist Pharmaceuticals is looking strong. |
American Family Physician
March 15, 2001
Thomas Hooton & Stuart Levy |
Antimicrobial Resistance: A Plan of Action for Community Practice Antibiotic resistance was once confined primarily to hospitals but is becoming increasingly prevalent in family practice settings, making daily therapeutic decisions more challenging. |
Managed Care
April 2000
Tim Olsen |
Physician, Tarnish Not Thine Image Doctors who use the news media to criticize others, rather than initiate a constructive dialog about difficult issues such as antibiotic resistance, help erode the profession's influence. |
